- Home
- LFST vs VCEL Comparison
LFST vs VCEL Comparison
Compare LFST & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- VCEL
- Stock Information
- Founded
- LFST 2015
- VCEL 1989
- Country
- LFST United States
- VCEL United States
- Employees
- LFST N/A
- VCEL N/A
- Industry
- LFST Medical/Nursing Services
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFST Health Care
- VCEL Health Care
- Exchange
- LFST Nasdaq
- VCEL Nasdaq
- Market Cap
- LFST 2.3B
- VCEL 2.1B
- IPO Year
- LFST 2021
- VCEL 1997
- Fundamental
- Price
- LFST $5.94
- VCEL $41.30
- Analyst Decision
- LFST Strong Buy
- VCEL Strong Buy
- Analyst Count
- LFST 5
- VCEL 8
- Target Price
- LFST $8.50
- VCEL $62.00
- AVG Volume (30 Days)
- LFST 2.0M
- VCEL 583.6K
- Earning Date
- LFST 05-07-2025
- VCEL 05-08-2025
- Dividend Yield
- LFST N/A
- VCEL N/A
- EPS Growth
- LFST N/A
- VCEL 521.85
- EPS
- LFST N/A
- VCEL 0.05
- Revenue
- LFST $1,283,503,000.00
- VCEL $238,541,000.00
- Revenue This Year
- LFST $15.35
- VCEL $23.03
- Revenue Next Year
- LFST $13.72
- VCEL $24.52
- P/E Ratio
- LFST N/A
- VCEL $698.09
- Revenue Growth
- LFST 16.31
- VCEL 14.80
- 52 Week Low
- LFST $4.64
- VCEL $37.39
- 52 Week High
- LFST $8.61
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- LFST 46.63
- VCEL 48.12
- Support Level
- LFST $5.47
- VCEL $40.38
- Resistance Level
- LFST $6.18
- VCEL $42.57
- Average True Range (ATR)
- LFST 0.20
- VCEL 1.69
- MACD
- LFST 0.05
- VCEL 0.06
- Stochastic Oscillator
- LFST 66.20
- VCEL 22.90
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.